New combo therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT03113500
First seen Nov 15, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 2 trial tests a combination of the targeted drug brentuximab vedotin plus standard chemotherapy in 48 people with CD30-positive peripheral T-cell lymphoma, a rare and aggressive blood cancer. The treatment aims to kill cancer cells more effectively by delivering a toxic agent directly to them. Researchers are measuring how many patients achieve complete remission and how long they survive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, etoposide, and prednisone
What this could lead to
If successful, this combination could become a standard first-line treatment for CD30-positive peripheral T-cell lymphoma, improving remission rates and survival.
What could go wrong
This is a small, single-center phase 2 study with only 48 participants. Results may not apply to all patients, and side effects from the chemotherapy and targeted drug can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.